Abstract: The invention relates to substitution derivatives of trisaccharide 3-fucosyl-N-acetyl lactosamine and to the immunological applications of these derivatives and of the trisaccharide itself particularly as diagnostic reagent and in therapy.

Abstract: Water soluble biologically active fraction obtainable from the physiologically inter-cellular medium bone-marrow and process for preparing said fraction and the pharmaceutical compositions containing said fraction. The characteristics are notably the following: it is substantially free of the inhibitors having molecular weights lower than 30,000; it is lyophilizable without loss of biological properties; it exhibits the biological activities in the form of a solution having a pH of at least 7; it stimulates H-thymidin incorporation by bone-marrow cells in vitro and in vivo; the water soluble fraction is capable of controlling the immune reactions of a host against allogenic cells or tissue.

Abstract: Mucopolysaccharides biologically active and more specific than heparin, particularly with respect to the blood factor Xa. These mucopolysaccharides may be obtained by partial depolymerisation, under controlled conditions, of heparin, by the action of a chemical agent such as nitrous acid. The conditions implemented allow the preparation of mucopolysaccharides having a USP titer lower than that of the starting heparin and a Yin-Wessler titer at least equal to that of said heparin. These products may be used particularly as antithrombotic drugs.

Abstract: The invention pertains to a mucopolysaccharide fraction obtainable from heparin or from fractions including heparinic constituents of molecular weights from 2,000 to 50,000, which has a Yin-Wessler titer which is high relative to the USP titer. It contains components whose molecular weights are less than 10,000, particularly oligosaccharides in the area of 2,000-3,000, comprising from 8 to 12, notably 10 monosaccharide units, among which glucosamine units whose primary positions are sulphated. The last mentioned oligosaccharides include one N-acetyl-glucosamine unit per two units of 2-0-sulphate iduronic acid and per two N-sulphate-glucosamine units, the other saccharide units being of a different nature and including distinct substituents.

Abstract: Oligopeptides having no more than 10 amino acids containing the sequence--(N-ter) A--X, --Gly--Y--Gly--X.sub.2 --A (C-ter)having the capacity of interacting with blood platelets and an ability to inhibit the aggregation of platelets induced by a collogen containing substance.

Abstract: Oligosaccharides obtainable from heparin including heparinic constituents of molecular weights ranging from 2000 to 50,000. Said fractions have a Yin-Wessler titer and a U.S.P. titer in a ratio of at least 30.They consist of chains constituted by no more than 8 saccharidic moities. They possess a strong antithrombotic activity and are then useful as antithrombotic drugs.

Abstract: The invention relates to trisubstituted sulfohalides, the process for their preparation and their use as intermediate products for the manufacture of novel compounds. The trisubstituted sulfohalides according to the invention correspond to the following general formula (I): ##STR1## in which: X is a halogen atom, particularly bromine or preferably chlorine;R.sub.3 and R.sub.4 each represent, independently of one another, a lower alkyl radical having from 1 to 4 carbon atoms, A represents hydrogen, halogen, alkoxy radicals having from 1 to 4 carbon atoms, alkylsulfonyl groups having from 1 to 4 carbon atoms, or the group NO.sub.2, or CF.sub.3. The invention is useful in the manufacture of medicaments.

Abstract: Oligosaccharides obtainable from heparin including heparinic constituents of molecular weights ranging from 2000 to 50,000. Said fractions have a Yin-Wessler titer and a USP titer in a ratio of at least 30. They consist of chains constituted by no more than 8 saccharidic moities. They possess a strong antithrombotic activity and are then useful as antithrombotic drugs.

Abstract: Oligosaccharides obtainable from heparin including heparinic constituents of molecular weights ranging from 2000 to 50,000. Said fractions have a Yin-Wessler titer and a USP titer in a ratio of at least 30.They consist of chains substituted by no more than 8 saccharidic moities. They possess a strong antithrombotic activity and are then useful as antithrombotic drugs.

Abstract: Heparin-based preparations wherein heparin is retained in or on liposomes.The lipids of said liposomes are preferably phospholipids comprising acyl chains derived from non saturated fatty acids, advantageously essential acids.These heparin-liposomes preparations have heparinic activity when administered in vivo by the oral route and a delayed-type action.

Abstract: New guanylhydrazones of phenoxyacetic acid. These guanylhydrazones, also their physiologically acceptable salts, are characterized by the following general formula I in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R and R' have the meanings which are hereinafter described. ##STR1## The new guanylhydrazones are useful as medicaments, in particular antimitotic, IMAO and platelet antiagregant activity.

Abstract: Amino-4 chloro-5 methoxy-2 N-(N-ethyl methyl-2 pyrrolidino) benzenesulfonamide is a novel compound corresponding to the formula ##STR1## and is prepared by reacting sulfonyl chloride of the formula ##STR2## with the amine of the formula ##STR3## This compound and its addition salts with physiologically acceptable mineral or organic acids, is a useful medicament for the treatment of ulcerous gastro-duodenal disorders.

Abstract: The invention relates to new N-substituted benzenesulphonamides of general formula ##STR1## in which n is 2 or 3,R.sub.1 and R.sub.2 are hydrogen atoms, methyl, ethyl groups, or jointly form with the nitrogen a nitrogenized heterocyclic ring having 5 or 6 members, in particular a piperidino, pyrrolidino or morpholino group.R.sub.3 is a hydrogen atom, an NO.sub.2 group, an NH.sub.2 group, or a halogen,R.sub.4 is a hydrogen, a halogen, NH.sub.2 group or a sulphonamide group.These compounds are useful as active substances of medicaments, in particular as antiemetic.

Abstract: The invention pertains to water soluble compositions having plasminogen activity capable of activation to plasmin formed of a mixture of different plasminogen compounds, among which native plasminogen and lysyl-plasminogen. It further concerns such compositions freed from the native plasminogen. They are obtained by the selective fixation of the other plasminogen compounds on fibrin. These compositions are useful for the production of pharmaceutical compositions.

Abstract: Mixed or simple heparin salt having a reduced amount of a selected metal ion alone or with another metal ion in a mixed heparin. A heparin salt having a reduced sodium content being essentially sodium free and having a selectively high calcium or other selected salt content. A process for making these heparin salts by reaction with the selected metal salt, including, optionally, dialysis or precipitation. A typical heparin salt is a calcium heparin essentially free of sodium (like containing less than about 1% by weight of sodium), or mixed calcium-sodium heparin with a limited, predetermined content of sodium. Drug compositions containing these heparin salts and a pharmaceutical carrier. The drugs made from these heparin salts are useful as anti-coagulants.

Abstract: A biologically active fraction of reduced toxicity or substantially free of it formed of components having molecular weights not exceeding 10,000-12,000, capable of stimulating in vivo the resistance to bacterial infections, is obtained from bacteria, more particularly Gram-negative bacteria.A process to that effect consists of subjecting a solution of an hydrosoluble crude bacterial extract to the action of an enzyme, such as DNase, which is capable of causing the irreversible detachment of the above said biologically active fraction from the hydrosoluble crude extract which can then be separated, such as by a filtration procedure, from the other components of the hydrosoluble crude extract. The latter can be obtained such as by the treatment of bacteria with a water-phenol mixture, preferably at a temperature above ambient, from about 60.degree. to about 70.degree. C., or by the action on bacteria of a detergent such as sodium dodecyl sulfate.

Abstract: The invention relates to the compound consisting of the peptide chain: leucyl - seryl - arginyl -leucyl - phenylalanyl -aspartyl - asparaginyl - alanine (I).This compound forms the active substances of drugs useful for the treatment of diabetes.

Abstract: The invention relates to novel derivatives of L-phenylalanine and particularly to tosyl-paraguanidino-L-phenylalanine methyl ester, to ter-butyloxycarbonyl derivative of para-guanidino-L-phenylalanine and to para-guanidino-L-phenylalanine.The tosyl-paraguanidino-L-phenylalanine methyl ester is an efficient trypsine substrate.

Abstract: The placental pulps notably of human origin are separated from the placental blood, which is removed, and the pulps are macerated in a solution at a pH comprised between 5 and 10, e.g. isotonic NaCl solution, preferably at neutral pH, in the presence of an amino-acid inhibitor of plasminogen activation, at a molar concentration comprised between about 0.001 and 0.1 M, preferably of the order of 0.035 M. The pulps are removed and the solution containing the compounds of the plasminogen type is recovered. Preferred inhibitors are L-lysine, epsilon aminocaproic acid, and trans-4 aminomethyl cyclohexane carboxylic acid.

Abstract: The present invention relates to the manufacture of new tablets for administration of medicaments, which tablets contain in their mass, controlled-release microcapsules, that is to say elemental particles coated with a protective covering which contains an encapsulated product which is gradually released in a controlled, regular and time-dependent way.These new tablets are characterized in that they are constituted by the association of a plurality of superposed layers of which the medial layer is essentially constituted by microcapsules containing an active substance, while the exterior layers constitute means of protecting the microcapsules of the medial layer, particularly against the shock of compression when compressing them to tablets. The invention thus relates to a process for manufacturing said tablets.